Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company’s Interim Chief Financial Officer since January 2023 and he served as the Company’s Corporate Controller prior to that since November 2021.

Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical, said, “Joe has been an instrumental leader to our finance and accounting team for the past few years and it will be a seamless transition as he steps into the permanent CFO role. With more than 25 years of experience in the public and private sectors including the life sciences industry, Joe’s in-depth financial and accounting knowledge and pharmaceutical experience are valuable assets to our company as we focus on our many upcoming milestones, including the potential approval of DFD-29 for the treatment of rosacea later this year. We look forward to Joe’s continued contributions to Journey Medical.”

Mr. Benesch has over 25 years of experience in all aspects of corporate financial leadership and reporting, technical accounting and controls, corporate controllership, regulatory and public company compliance, treasury and pharmaceutical company operations. Prior to joining Journey Medical, Mr. Benesch previously served as the Principal Accounting Officer, Vice President and Corporate Controller of Teligent Pharma Inc., a specialty generic pharmaceutical company, and Corporate Controller of Torrent Pharmaceuticals, a U.S. subsidiary of the Torrent Group, a multinational pharmaceutical company. Before joining Torrent, he held senior financial management positions of increasing responsibility from Corporate Controller to Vice President of Finance at Savient Pharmaceuticals, Adare Pharmaceuticals and Edenbridge Pharmaceuticals. Mr. Benesch began his career in the public accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young working with a diverse client base. Mr. Benesch is a graduate of Wilkes University where he earned a BA in accounting and is a Certified Public Accountant.